|
November
Monday, Nov 17, 2008 Genentech Issues Dear Healthcare Provider Letter Regarding a 2nd Case of PML in a Raptiva Patient Thursday, Nov 06, 2008 Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer Monday, Nov 03, 2008 Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer October Monday, Oct 27, 2008 Rituxan Data in Patients With Rheumatoid Arthritis To Be Presented at The American College of Rheumatology Annual Scientific Meeting Sunday, Oct 19, 2008 Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue Tuesday, Oct 14, 2008 Genentech Announces Third Quarter 2008 Results Monday, Oct 06, 2008 Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia Sunday, Oct 05, 2008 Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer Thursday, Oct 02, 2008 Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient Thursday, Oct 02, 2008 Genentech, Glycart and Roche Enter Into Collaboration Agreement for Potential Cancer Therapy September Tuesday, Sep 23, 2008 Genentech Announces October 14 Webcast of Financial and Other Business Results Wednesday, Sep 10, 2008 Genentech Announces Vice President Appointment In Research See the Archives 
 |
